{"id":"NCT04444895","sponsor":"Shire","briefTitle":"A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor","officialTitle":"An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-05","primaryCompletion":"2023-05-05","completion":"2023-05-05","firstPosted":"2020-06-24","resultsPosted":"2024-06-17","lastUpdate":"2024-06-17"},"enrollment":73,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Angioedema"],"interventions":[{"type":"DRUG","name":"Lanadelumab","otherNames":["DX-2930","SHP643","TAK-743"]}],"arms":[{"label":"Lanadelumab 300 mg Every 2 Weeks","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and efficacy of repeated subcutaneous (SC) administration of lanadelumab in adolescents and adults with non-histaminergic angioedema with normal C1-inhibitor who completed study SHP643-303 (NCT04206605).","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) During Treatment Period","timeFrame":"From Day 0 up to Day 182","effectByArm":[{"arm":"Lanadelumab 300 mg Q2W","deltaMin":55,"sd":null},{"arm":"Lanadelumab 300 mg Q4W","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":35,"countries":["United States","Canada","France","Germany","Hungary","Italy","Japan","Netherlands","Poland","Spain"]},"refs":{"pmids":["40469312"],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b600d4db2bf003ab48cf1?idFilter=%5B%22TAK-743-3001%22%5D"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":73},"commonTop":["Angioedema","COVID-19","Headache","Injection site pain","Arthralgia"]}}